About

PROTEINA has developed the first-in-class “Single-Molecule Co-Immunoprecipitation”-based general platform, which enables precise measurement of protein-protein interactions (PPIs) at the single-molecular level. At PROTEINA, we've spent over a decade delving into the intricacies of protein-protein interactions. The wealth of knowledge and experience we've gained is reflected in our diverse range of research services and products that we offer to our clients and research partners. These offerings include biomarker discovery for drug development, deciphering the mechanisms of pharmaceutical compounds, and identifying the ideal drug dose of a specific drug treatment. Ultimately, we see our goal of developing accurate, reliable companion diagnostic devices slowly become a reality. The outstanding efforts of the individuals who make up PROTEINA have been gaining recognition through the numerous collaborations and service contracts with well-established pharmaceutical and biotechnology organizations over the years. Our journey began in a small university laboratory over a decade ago, but we have grown to possess the capacity to create cutting-edge technology that is highly valued in the current market. Today, we continue to strive to establish ourselves as a strong competitive force in the global environment. My ultimate goal for PROTEINA is to make meaningful contributions to society by facilitating scientific breakthroughs and innovations. To achieve this, we are committed to attracting and retaining top talent who share our mission. We also strive to maintain a corporate culture that encourages open communication and collaboration among all team members, ensuring that we arrive at the best solutions collectively. With the help of our talented pool of professionals, we aim to further enhance PROTEINA's technology. By doing so, our products and services will play a critical role in advancing the development of new drugs to combat a wide range of serious illnesses. This, in turn, will be the driving force behind our growth from a company into a global organization. About PROTEINA PROTEINA is a precision therapeutics company translating protein interaction biology into next-generation drugs. Our proprietary SPID platform generates quantitative PPI data at a scale and resolution unavailable with conventional methods — fueling our commercial services, internal pipeline, and AbGPT-3D. Lead programs include PRT-101, a preclinical DMOAD for osteoarthritis, and PRT-1309, a GIPR antagonist antibody targeting obesity and metabolic disease. Our platform anchors a ₩47B national consortium with Samsung Bioepis. We are looking for licensing and co-development partners.